Monoclonal antibody to vascular endothelial-cadherin is a potent inhibitor of angiogenesis, tumor growth, and metastasis

Francesca-Fang Liao, Yiwen Li, William O’Connor, Lucia Zanetta, Rajiv Bassi, Angel Santiago, Jay Overholser, Andrea Hooper, Paolo Mignatti, Elisabetta Dejana, Daniel J. Hicklin, Peter Bohlen

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

Vascular endothelial-cadherin (VE-cad) is an endothelial cell-specific adhesion molecule that is crucial for proper assembly of vascular tubes. Here we show that a monoclonal antibody (BV13) directed to the extracellular region of VE-cad inhibits formation of adherens junctions and capillary-like structures by endothelial cells and blocks angiogenesis in the mouse cornea and in Matrigel plugs in vivo. Systemic administration of BV13 markedly decreases the growth of s.c. Lewis lung or human A431 epidermoid tumors and strongly suppresses the growth of Lewis lung metastases. These data demonstrate that VE-cad is essential for postnatal angiogenesis and thus validate VE-cad as a novel target for antiangiogenesis agents.

Original languageEnglish (US)
Pages (from-to)6805-6810
Number of pages6
JournalCancer Research
Volume60
Issue number24
StatePublished - Dec 15 2000

Fingerprint

Angiogenesis Inhibitors
Monoclonal Antibodies
Neoplasm Metastasis
Growth
Neoplasms
Endothelial Cells
Adherens Junctions
Lung
Cell Adhesion Molecules
Cornea
Blood Vessels
cadherin 5

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Liao, F-F., Li, Y., O’Connor, W., Zanetta, L., Bassi, R., Santiago, A., ... Bohlen, P. (2000). Monoclonal antibody to vascular endothelial-cadherin is a potent inhibitor of angiogenesis, tumor growth, and metastasis. Cancer Research, 60(24), 6805-6810.

Monoclonal antibody to vascular endothelial-cadherin is a potent inhibitor of angiogenesis, tumor growth, and metastasis. / Liao, Francesca-Fang; Li, Yiwen; O’Connor, William; Zanetta, Lucia; Bassi, Rajiv; Santiago, Angel; Overholser, Jay; Hooper, Andrea; Mignatti, Paolo; Dejana, Elisabetta; Hicklin, Daniel J.; Bohlen, Peter.

In: Cancer Research, Vol. 60, No. 24, 15.12.2000, p. 6805-6810.

Research output: Contribution to journalArticle

Liao, F-F, Li, Y, O’Connor, W, Zanetta, L, Bassi, R, Santiago, A, Overholser, J, Hooper, A, Mignatti, P, Dejana, E, Hicklin, DJ & Bohlen, P 2000, 'Monoclonal antibody to vascular endothelial-cadherin is a potent inhibitor of angiogenesis, tumor growth, and metastasis', Cancer Research, vol. 60, no. 24, pp. 6805-6810.
Liao, Francesca-Fang ; Li, Yiwen ; O’Connor, William ; Zanetta, Lucia ; Bassi, Rajiv ; Santiago, Angel ; Overholser, Jay ; Hooper, Andrea ; Mignatti, Paolo ; Dejana, Elisabetta ; Hicklin, Daniel J. ; Bohlen, Peter. / Monoclonal antibody to vascular endothelial-cadherin is a potent inhibitor of angiogenesis, tumor growth, and metastasis. In: Cancer Research. 2000 ; Vol. 60, No. 24. pp. 6805-6810.
@article{1626d0fe0a324744a00519529767dc67,
title = "Monoclonal antibody to vascular endothelial-cadherin is a potent inhibitor of angiogenesis, tumor growth, and metastasis",
abstract = "Vascular endothelial-cadherin (VE-cad) is an endothelial cell-specific adhesion molecule that is crucial for proper assembly of vascular tubes. Here we show that a monoclonal antibody (BV13) directed to the extracellular region of VE-cad inhibits formation of adherens junctions and capillary-like structures by endothelial cells and blocks angiogenesis in the mouse cornea and in Matrigel plugs in vivo. Systemic administration of BV13 markedly decreases the growth of s.c. Lewis lung or human A431 epidermoid tumors and strongly suppresses the growth of Lewis lung metastases. These data demonstrate that VE-cad is essential for postnatal angiogenesis and thus validate VE-cad as a novel target for antiangiogenesis agents.",
author = "Francesca-Fang Liao and Yiwen Li and William O’Connor and Lucia Zanetta and Rajiv Bassi and Angel Santiago and Jay Overholser and Andrea Hooper and Paolo Mignatti and Elisabetta Dejana and Hicklin, {Daniel J.} and Peter Bohlen",
year = "2000",
month = "12",
day = "15",
language = "English (US)",
volume = "60",
pages = "6805--6810",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - Monoclonal antibody to vascular endothelial-cadherin is a potent inhibitor of angiogenesis, tumor growth, and metastasis

AU - Liao, Francesca-Fang

AU - Li, Yiwen

AU - O’Connor, William

AU - Zanetta, Lucia

AU - Bassi, Rajiv

AU - Santiago, Angel

AU - Overholser, Jay

AU - Hooper, Andrea

AU - Mignatti, Paolo

AU - Dejana, Elisabetta

AU - Hicklin, Daniel J.

AU - Bohlen, Peter

PY - 2000/12/15

Y1 - 2000/12/15

N2 - Vascular endothelial-cadherin (VE-cad) is an endothelial cell-specific adhesion molecule that is crucial for proper assembly of vascular tubes. Here we show that a monoclonal antibody (BV13) directed to the extracellular region of VE-cad inhibits formation of adherens junctions and capillary-like structures by endothelial cells and blocks angiogenesis in the mouse cornea and in Matrigel plugs in vivo. Systemic administration of BV13 markedly decreases the growth of s.c. Lewis lung or human A431 epidermoid tumors and strongly suppresses the growth of Lewis lung metastases. These data demonstrate that VE-cad is essential for postnatal angiogenesis and thus validate VE-cad as a novel target for antiangiogenesis agents.

AB - Vascular endothelial-cadherin (VE-cad) is an endothelial cell-specific adhesion molecule that is crucial for proper assembly of vascular tubes. Here we show that a monoclonal antibody (BV13) directed to the extracellular region of VE-cad inhibits formation of adherens junctions and capillary-like structures by endothelial cells and blocks angiogenesis in the mouse cornea and in Matrigel plugs in vivo. Systemic administration of BV13 markedly decreases the growth of s.c. Lewis lung or human A431 epidermoid tumors and strongly suppresses the growth of Lewis lung metastases. These data demonstrate that VE-cad is essential for postnatal angiogenesis and thus validate VE-cad as a novel target for antiangiogenesis agents.

UR - http://www.scopus.com/inward/record.url?scp=0034671549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034671549&partnerID=8YFLogxK

M3 - Article

VL - 60

SP - 6805

EP - 6810

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 24

ER -